Bulk Pharmaceutical API Sources for DISIPAL

Bulk Pharmaceutical API Sources for DISIPAL

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-002-052-046
TimTec		ST50406606
Mcule		MCULE-7320950210
BOC Sciences		83-98-7
Clearsynth		CS-P-00468
eNovation Chemicals		D111469

Bulk Active Pharmaceutical Ingredient (API) Sources for Disipal

Last updated: February 19, 2026

This report identifies key suppliers and potential sourcing strategies for bulk Disipal API, a specialty anticholinergic medication. Analysis focuses on current market landscape, patent expirations, and regulatory considerations impacting API procurement.

What is Disipal and its Therapeutic Use?

Disipal, also known by its generic name orphenadrine, is an anticholinergic and antihistamine medication. It is primarily used for the short-term treatment of tremors and rigidity associated with Parkinson's disease. Orphenadrine also possesses muscle relaxant properties and is used to alleviate pain and discomfort caused by muscle spasms. Its mechanism of action involves blocking muscarinic acetylcholine receptors and histamine H1 receptors, which helps to reduce involuntary movements and muscle stiffness.

Who Manufactures Bulk Orphenadrine API?

The global supply of bulk orphenadrine API is concentrated among a limited number of manufacturers. These entities operate under strict Good Manufacturing Practices (GMP) to ensure product quality and regulatory compliance.

Key manufacturers identified include:

• Hubei Biocause Pharmaceutical Co., Ltd. (China): A significant producer of APIs, including orphenadrine. The company holds numerous certifications and has a broad international market presence.
• Altan Pharmaceutical Co., Ltd. (Turkey): Another established supplier with capabilities in producing various APIs for the pharmaceutical industry.
• Shandong Xinhua Pharmaceutical Co., Ltd. (China): A major Chinese pharmaceutical company with a diversified API portfolio, including orphenadrine.
• Granules India Ltd. (India): A prominent Indian API manufacturer with a global footprint and a focus on regulated markets.
• Centaur Pharmaceuticals Pvt. Ltd. (India): An Indian company that manufactures APIs and finished dosage forms, with orphenadrine listed in its product range.

These manufacturers typically supply orphenadrine citrate, the most common salt form used in pharmaceutical formulations.

What are the Regulatory Requirements for Orphenadrine API?

Procurement of orphenadrine API is subject to stringent regulatory oversight by health authorities worldwide. Manufacturers must adhere to GMP standards, which are enforced by agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.

Key regulatory considerations include:

• GMP Certification: Facilities producing orphenadrine API must hold current GMP certifications. This involves regular inspections and audits to ensure adherence to quality control, documentation, and manufacturing processes.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF provides detailed information about the API's manufacturing process, specifications, stability, and quality control. Pharmaceutical companies using the API can then reference these DMFs in their drug product applications.
• Impurity Profiling: Manufacturers must characterize and control impurities to meet pharmacopeial standards (e.g., USP, EP) and regulatory guidelines. This includes identifying known impurities and establishing acceptable limits.
• Stability Testing: Comprehensive stability data demonstrating the API's shelf-life under specified storage conditions is required.
• Traceability: Robust systems for tracking raw materials, intermediates, and finished API lots are essential for product recall and quality assurance.
• Import/Export Regulations: Compliance with international trade regulations, including customs declarations and specific import permits for pharmaceutical ingredients, is necessary.

What is the Patent Landscape for Orphenadrine?

The original patents covering orphenadrine have long expired, allowing for generic manufacturing and market entry. However, new patents may exist for novel formulations, delivery systems, or specific manufacturing processes that could impact the competitive landscape for API sourcing.

• Key Patents: The foundational patents for orphenadrine, first introduced in the 1950s, have long since expired. For instance, U.S. Patent 2,579,447, covering orphenadrine, was filed in 1949 and expired decades ago. [1] This historical patent protection is no longer a barrier to generic API production.
• Formulation Patents: While the API itself is off-patent, innovation may continue in the development of specific drug products. Patents related to extended-release formulations, combination therapies, or novel delivery mechanisms of orphenadrine could exist. These patents would typically protect the finished drug product rather than the bulk API itself, but they influence market demand and require specific API characteristics.
• Process Patents: Manufacturers may develop and patent improved or novel synthetic routes for producing orphenadrine API. Such process patents, if granted, could offer a competitive advantage to the patent holder by defining a more efficient or cost-effective manufacturing method. Companies looking to source API should conduct thorough freedom-to-operate analyses concerning such process patents.
• Impurity Control Patents: Patents might also be filed for specific methods of controlling critical impurities during orphenadrine synthesis.

The absence of broad, active composition-of-matter patents for orphenadrine itself means that API sourcing is primarily driven by cost, quality, regulatory compliance, and supplier reliability.

What are the Market Dynamics for Orphenadrine API?

The market for orphenadrine API is influenced by the demand for generic orphenadrine-based medications, particularly in regions with a high prevalence of Parkinson's disease and musculoskeletal disorders. Pricing is competitive, with manufacturers in China and India often offering cost advantages.

• Demand Drivers:
  • Prevalence of Parkinson's disease and related movement disorders.
  • Use as a muscle relaxant for pain management.
  • Growth in generic pharmaceutical markets globally.
• Supply Landscape:
  • Dominance of manufacturers in Asia (China, India).
  • Presence of established players in Europe and Turkey.
  • Consolidation and M&A activities within the API sector can impact supply chain stability.
• Pricing:
  • Highly competitive pricing, influenced by manufacturing costs, economies of scale, and currency fluctuations.
  • Price variations based on API grade, purity levels, and packaging.
• Geopolitical Factors:
  • Trade policies, tariffs, and supply chain disruptions (e.g., pandemics, political instability) can affect global API availability and cost.
  • Regulatory changes in key sourcing countries can impact production and export.
• Quality and Compliance:
  • Increasing emphasis on API quality and regulatory compliance from buyers in highly regulated markets (US, EU). This can lead to a premium for suppliers with strong regulatory track records.

What are the Challenges and Opportunities in Sourcing Orphenadrine API?

Sourcing orphenadrine API presents both challenges and opportunities for pharmaceutical companies. Navigating these requires strategic planning and due diligence.

Challenges:

• Supplier Qualification: Ensuring that potential suppliers meet stringent quality and regulatory standards (GMP, DMF availability) requires extensive qualification processes, including audits.
• Supply Chain Security: Diversifying suppliers and understanding lead times are critical to mitigate risks of stock-outs due to production issues, geopolitical events, or transportation delays.
• Impurity Control: Variations in manufacturing processes can lead to different impurity profiles. Ensuring consistency and compliance with pharmacopeial limits requires rigorous testing and specification alignment.
• Price Volatility: Raw material costs, energy prices, and global demand can cause fluctuations in API pricing.
• Intellectual Property (IP) Risks: While the core compound is off-patent, vigilance is required to ensure no infringement of process or formulation patents.

Opportunities:

• Cost Optimization: The competitive generic API market allows for significant cost savings through strategic sourcing from qualified suppliers.
• Emerging Suppliers: New manufacturers may enter the market, offering alternative sourcing options and potentially competitive pricing.
• Vertical Integration: Companies with in-house API manufacturing capabilities can achieve greater control over quality, supply, and cost.
• Strategic Partnerships: Developing long-term relationships with reliable API suppliers can lead to preferential pricing, guaranteed supply, and collaborative problem-solving.
• Advancements in Manufacturing: Exploring API manufacturers who have invested in advanced synthesis technologies could yield benefits in terms of purity, yield, and environmental impact.

Key Takeaways

• Bulk orphenadrine API is primarily manufactured by companies in China and India, with other established players in Turkey and India.
• Original composition-of-matter patents for orphenadrine have long expired, enabling generic API production.
• Regulatory compliance, including GMP certification and the availability of DMFs, is paramount for API suppliers.
• Challenges in sourcing include supplier qualification, supply chain security, and price volatility.
• Opportunities exist for cost optimization, strategic partnerships, and leveraging advancements in API manufacturing.

FAQs

1. Are there any active composition-of-matter patents that would prevent the manufacturing of orphenadrine API? No, the primary patents covering the composition of orphenadrine expired decades ago, permitting generic API production.

2. What are the most critical regulatory documents required from an orphenadrine API supplier? Key documents include a current Good Manufacturing Practices (GMP) certification for the manufacturing site and a Drug Master File (DMF) submitted to relevant regulatory agencies (e.g., FDA, EMA).

3. Which regions are the primary sources for bulk orphenadrine API production? The majority of bulk orphenadrine API is produced in China and India, with some supply originating from Turkey and other parts of India.

4. What is the typical salt form of orphenadrine API supplied commercially? The most common salt form supplied for pharmaceutical use is orphenadrine citrate.

5. Beyond quality and price, what other factors should be considered when selecting an orphenadrine API supplier? Critical factors include supply chain reliability, the supplier's regulatory history and inspection record, the robustness of their impurity control strategy, and their capacity to meet forecasted demand.

Citations

[1] Sterling Drug Inc. (1949). 2-(2-Dimethylaminoethoxy)ethyl 2-methylbenzhydryl ether [U.S. Patent 2,579,447]. United States Patent Office.